Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $11.13.

Several brokerages have commented on STRO. JMP Securities reaffirmed a "market outperform" rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Wells Fargo & Company cut their target price on shares of Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating for the company in a research note on Wednesday, December 11th. HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Sutro Biopharma in a research report on Monday, November 18th. Piper Sandler reissued an "overweight" rating and set a $11.00 target price on shares of Sutro Biopharma in a research report on Friday, October 11th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $8.00 price target on shares of Sutro Biopharma in a report on Tuesday, December 10th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in STRO. SG Americas Securities LLC increased its position in shares of Sutro Biopharma by 16.6% during the 4th quarter. SG Americas Securities LLC now owns 40,432 shares of the company's stock worth $74,000 after purchasing an additional 5,770 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Sutro Biopharma in the third quarter valued at approximately $77,000. Barclays PLC boosted its holdings in shares of Sutro Biopharma by 385.3% in the 3rd quarter. Barclays PLC now owns 273,019 shares of the company's stock worth $944,000 after acquiring an additional 216,757 shares in the last quarter. Geode Capital Management LLC grew its position in Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company's stock worth $6,426,000 after acquiring an additional 132,015 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in Sutro Biopharma by 222.0% during the 3rd quarter. XTX Topco Ltd now owns 104,200 shares of the company's stock valued at $361,000 after purchasing an additional 71,844 shares in the last quarter. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Stock Performance

Shares of NASDAQ:STRO traded up $0.16 during midday trading on Friday, hitting $2.01. The company's stock had a trading volume of 1,309,170 shares, compared to its average volume of 892,331. The stock's 50 day simple moving average is $2.42 and its 200 day simple moving average is $3.34. The stock has a market capitalization of $165.74 million, a price-to-earnings ratio of -1.25 and a beta of 1.15. Sutro Biopharma has a fifty-two week low of $1.67 and a fifty-two week high of $6.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.